SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

26 Jul 2024 Evaluate
The revenue for the June 2024 quarter is pegged at Rs. 45010.50 millions, about 14.77% up against Rs. 39219.00 millions recorded during the year-ago period.A comparatively good net profit growth of 32.18% to Rs. 10559.40 millions was reported for the quarter ended June 2024 compared to Rs. 7988.80 millions of previous same quarter.Operating profit for the quarter ended June 2024 rose to 15733.80 millions as compared to 12341.90 millions of corresponding quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 45010.50 39219.00 14.77 45010.50 39219.00 14.77 165743.40 143453.40 15.54
Other Income 2135.20 1579.80 35.16 2135.20 1579.80 35.16 10706.60 4567.90 134.39
PBIDT 15733.80 12341.90 27.48 15733.80 12341.90 27.48 55548.10 38096.80 45.81
Interest 50.70 3.10 1535.48 50.70 3.10 1535.48 202.50 222.70 -9.07
PBDT 15683.10 12338.80 27.10 15683.10 12338.80 27.10 55345.60 36015.10 53.67
Depreciation 1378.60 1359.50 1.40 1378.60 1359.50 1.40 5875.90 5959.10 -1.40
PBT 14304.50 10979.30 30.29 14304.50 10979.30 30.29 49469.70 30056.00 64.59
TAX 3745.10 2990.50 25.23 3745.10 2990.50 25.23 12327.80 8615.40 43.09
Deferred Tax 165.90 -89.50 -285.36 165.90 -89.50 -285.36 60.90 -400.90 -115.19
PAT 10559.40 7988.80 32.18 10559.40 7988.80 32.18 37141.90 21440.60 73.23
Equity 1615.00 1614.50 0.03 1615.00 1614.50 0.03 1614.70 1614.30 0.02
PBIDTM(%) 34.96 31.47 11.08 34.96 31.47 11.08 33.51 26.56 26.20

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×